1. Home
  2. ASG vs SGHT Comparison

ASG vs SGHT Comparison

Compare ASG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty All-Star Growth Fund Inc.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.01

Market Cap

321.1M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$8.14

Market Cap

309.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASG
SGHT
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
321.1M
309.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
ASG
SGHT
Price
$5.01
$8.14
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
210.6K
176.6K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.55
$3.19
52 Week High
$5.69
$9.24

Technical Indicators

Market Signals
Indicator
ASG
SGHT
Relative Strength Index (RSI) 34.38 60.54
Support Level $4.98 $8.00
Resistance Level $5.40 $8.80
Average True Range (ATR) 0.05 0.36
MACD -0.02 -0.14
Stochastic Oscillator 9.38 46.79

Price Performance

Historical Comparison
ASG
SGHT

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: